Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintained.

Pinzone MR, O'Doherty U.

Retrovirology. 2018 Feb 17;15(1):22. doi: 10.1186/s12977-018-0396-3. Review.

2.

A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.

Abner E, Stoszko M, Zeng L, Chen HC, Izquierdo-Bouldstridge A, Konuma T, Zorita E, Fanunza E, Zhang Q, Mahmoudi T, Zhou MM, Filion GJ, Jordan A.

J Virol. 2018 Apr 27;92(10). pii: e02056-17. doi: 10.1128/JVI.02056-17. Print 2018 May 15.

PMID:
29343578
3.

Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure.

Khan S, Telwatte S, Trapecar M, Yukl S, Sanjabi S.

AIDS Res Hum Retroviruses. 2017 Nov;33(S1):S40-S58. doi: 10.1089/AID.2017.0153.

PMID:
28882067
4.

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation.

Albert BJ, Niu A, Ramani R, Marshall GR, Wender PA, Williams RM, Ratner L, Barnes AB, Kyei GB.

Sci Rep. 2017 Aug 7;7(1):7456. doi: 10.1038/s41598-017-07814-4.

5.

Dendritic cells maturated by co-culturing with HIV-1 latently infected Jurkat T cells or stimulating with AIDS-associated pathogens secrete TNF-α to reactivate HIV-1 from latency.

Ren XX, Ma L, Sun WW, Kuang WD, Li TS, Jin X, Wang JH.

Virulence. 2017 Nov 17;8(8):1732-1743. doi: 10.1080/21505594.2017.1356535. Epub 2017 Aug 16.

PMID:
28762863
6.

Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.

Bonczkowski P, De Scheerder MA, Malatinkova E, Borch A, Melkova Z, Koenig R, De Spiegelaere W, Vandekerckhove L.

Sci Rep. 2016 Dec 2;6:38329. doi: 10.1038/srep38329.

7.

Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro.

Anderson JL, Mota TM, Evans VA, Kumar N, Rezaei SD, Cheong K, Solomon A, Wightman F, Cameron PU, Lewin SR.

PLoS One. 2016 Jul 6;11(7):e0158778. doi: 10.1371/journal.pone.0158778. eCollection 2016.

8.

Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.

Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, Greene WC, Wong JK.

Nat Med. 2016 Jul;22(7):807-11. doi: 10.1038/nm.4124. Epub 2016 Jun 13.

9.

Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.

Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, Kan TW, Boucher C, Verbon A, Dykhuizen EC, Mahmoudi T.

EBioMedicine. 2015 Nov 27;3:108-121. doi: 10.1016/j.ebiom.2015.11.047. eCollection 2016 Jan.

10.

HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells.

Chan CN, Trinité B, Lee CS, Mahajan S, Anand A, Wodarz D, Sabbaj S, Bansal A, Goepfert PA, Levy DN.

Retrovirology. 2016 Jan 5;13:1. doi: 10.1186/s12977-015-0234-9.

11.

Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.

Pallikkuth S, Sharkey M, Babic DZ, Gupta S, Stone GW, Fischl MA, Stevenson M, Pahwa S.

J Virol. 2015 Dec 16;90(6):2718-28. doi: 10.1128/JVI.02883-15.

12.

Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.

Sloan DD, Lam CY, Irrinki A, Liu L, Tsai A, Pace CS, Kaur J, Murry JP, Balakrishnan M, Moore PA, Johnson S, Nordstrom JL, Cihlar T, Koenig S.

PLoS Pathog. 2015 Nov 5;11(11):e1005233. doi: 10.1371/journal.ppat.1005233. eCollection 2015.

13.

Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1.

Arenaccio C, Anticoli S, Manfredi F, Chiozzini C, Olivetta E, Federico M.

Retrovirology. 2015 Oct 26;12:87. doi: 10.1186/s12977-015-0216-y.

14.

Progress and challenges in the use of latent HIV-1 reactivating agents.

Shang HT, Ding JW, Yu SY, Wu T, Zhang QL, Liang FJ.

Acta Pharmacol Sin. 2015 Aug;36(8):908-16. doi: 10.1038/aps.2015.22. Epub 2015 Jun 1. Review.

15.

Blimp-1, an intrinsic factor that represses HIV-1 proviral transcription in memory CD4+ T cells.

Kaczmarek Michaels K, Natarajan M, Euler Z, Alter G, Viglianti G, Henderson AJ.

J Immunol. 2015 Apr 1;194(7):3267-74. doi: 10.4049/jimmunol.1402581. Epub 2015 Feb 20.

16.

Immuno-modulatory strategies for reduction of HIV reservoir cells.

Banks HT, Flores KB, Hu S, Rosenberg E, Buzon M, Yu X, Lichterfeld M.

J Theor Biol. 2015 May 7;372:146-58. doi: 10.1016/j.jtbi.2015.02.006. Epub 2015 Feb 17.

17.

Understanding HIV latency: the road to an HIV cure.

Dahabieh MS, Battivelli E, Verdin E.

Annu Rev Med. 2015;66:407-21. doi: 10.1146/annurev-med-092112-152941. Review.

18.

HIV eradication: combinatorial approaches to activate latent viruses.

De Crignis E, Mahmoudi T.

Viruses. 2014 Nov 21;6(11):4581-608. doi: 10.3390/v6114581. Review.

19.

Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM.

Nat Rev Microbiol. 2014 Nov;12(11):750-64. doi: 10.1038/nrmicro3352. Review.

20.

Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.

Miller EA, Spadaccia MR, Norton T, Demmler M, Gopal R, O'Brien M, Landau N, Dubensky TW Jr, Lauer P, Brockstedt DG, Bhardwaj N.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):127-36. doi: 10.1089/AID.2014.0138.

Supplemental Content

Support Center